Structure elucidation of a human melanocortin-4 receptor specific orthosteric nanobody agonist

Thomas Fontaine,Andreas Busch,Toon Laeremans,Stéphane De Cesco,Yi-Lynn Liang,Veli-Pekka Jaakola,Zara Sands,Sarah Triest,Simonas Masiulis,Lies Dekeyzer,Noor Samyn,Nicolas Loeys,Lisa Perneel,Melanie Debaere,Murielle Martini,Charlotte Vantieghem,Richa Virmani,Kamila Skieterska,Stephanie Staelens,Rosa Barroco,Maarten Van Roy,Christel Menet
DOI: https://doi.org/10.1038/s41467-024-50827-7
2024-10-01
Abstract:The melanocortin receptor 4 (MC4R) belongs to the melanocortin receptor family of G-protein coupled receptors and is a key switch in the leptin-melanocortin molecular axis that controls hunger and satiety. Brain-produced hormones such as α-melanocyte-stimulating hormone (agonist) and agouti-related peptide (inverse agonist) regulate the molecular communication of the MC4R axis but are promiscuous for melanocortin receptor subtypes and induce a wide array of biological effects. Here, we use a chimeric construct of conformation-selective, nanobody-based binding domain (a ConfoBody Cb80) and active state-stabilized MC4R-β2AR hybrid for efficient de novo discovery of a sequence diverse panel of MC4R-specific, potent and full agonistic nanobodies. We solve the active state MC4R structure in complex with the full agonistic nanobody pN162 at 3.4 Å resolution. The structure shows a distinct interaction with pN162 binding deeply in the orthosteric pocket. MC4R peptide agonists, such as the marketed setmelanotide, lack receptor selectivity and show off-target effects. In contrast, the agonistic nanobody is highly specific and hence can be a more suitable agent for anti-obesity therapeutic intervention via MC4R.
What problem does this paper attempt to address?